Objective: To observe the effect of Xueyou Mixture (血友合剂, XYM) on blood coagulation factors and its safety in treating hemophilia. Methods: To the randomly selected 65 inpatients of hemophilia, XYM was administered accompanied with intravenous dripping of liver cell growth factor 60-100 mg once a day to protect the liver, with no blood products like concentrated Ⅷ and FⅨ factors or blood plasma given. The treatment lasted for 3 weeks. The short-term efficacy and adverse reactions were observed. The long-term efficacy in patients was observed in a follow-up study of 6-12 months after they were discharged from the hospital but continuously took XYM orally. Results: The short-term markedly effective rate in the patients was 95.38% (62/65). After they were treated for 3 weeks, the level of FⅧ factor activity increased in 56 patients of type A from (3.32 ± 2.21) % to (4.18 ± 2.23) %, and in 9 of type B from (4.92 ± 1.81) % to (5.64 ± 1.96) %. Compared with that before treatment, the difference was significant in both of them (P＜0.01). No obvious adverse reaction was found in the treatment period.The follow-up study showed that in 22 patients of type A, the FⅧ factor activity ratio increased from (3.25±2.11) % to (6.31 ±2.16) %, (8.36±1.05) %, and (16.38±2.71) % in the 2nd, 3rd and 6th month after discharge respectively, all showing significant difference to that before treatment (P＜0.01); and in 4 patients of type B, it increased from (4.15 ± 2.26) % to 7.8% and 11.6% (mean value) in the 2nd and 6th month respectively. Conclusion: XYM could raise the activity of factors Ⅷ and Ⅸ in patients with hemophilia, and the degree of the rise is related with the duration of the therapy, with no obvious adverse reaction, which strikes out a new path and new train of thinking for the treatment of the disease by nonblood preparation.